256 related articles for article (PubMed ID: 16387749)
1. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
Lewis RE; Wiederhold NP; Prince RA; Kontoyiannis DP
J Antimicrob Chemother; 2006 Feb; 57(2):288-93. PubMed ID: 16387749
[TBL] [Abstract][Full Text] [Related]
2. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis.
Kretschmar M; Nichterlein T; Hannak D; Hof H
Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model.
Lignell A; Löwdin E; Cars O; Sjölin J
J Antimicrob Chemother; 2008 Jul; 62(1):142-8. PubMed ID: 18408237
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
Andes D; Safdar N; Marchillo K; Conklin R
Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
[TBL] [Abstract][Full Text] [Related]
5. A new in-vitro kinetic model to study the pharmacodynamics of antifungal agents: inhibition of the fungicidal activity of amphotericin B against Candida albicans by voriconazole.
Lignell A; Johansson A; Löwdin E; Cars O; Sjölin J
Clin Microbiol Infect; 2007 Jun; 13(6):613-9. PubMed ID: 17378925
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.
Groll AH; Giri N; Petraitis V; Petraitiene R; Candelario M; Bacher JS; Piscitelli SC; Walsh TJ
J Infect Dis; 2000 Jul; 182(1):274-82. PubMed ID: 10882607
[TBL] [Abstract][Full Text] [Related]
7. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome.
Atkinson BJ; Lewis RE; Kontoyiannis DP
Med Mycol; 2008 Sep; 46(6):541-6. PubMed ID: 19180749
[TBL] [Abstract][Full Text] [Related]
8. Amphotericin B dose optimization in children with malignant diseases.
Nath CE; McLachlan AJ; Shaw PJ; Coakley JC; Earl JW
Chemotherapy; 2007; 53(2):142-7. PubMed ID: 17310120
[TBL] [Abstract][Full Text] [Related]
9. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
[TBL] [Abstract][Full Text] [Related]
10. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
11. [Emulsion of amphotericin B in Intralipid 20%: in vitro and in vivo efficacy].
Chavanet P; Charlier N; Brenet A; Goux A; Muggéo E; Caillot D; Casasnovas O; Kistermann JP; Waldner A; Portier H
Pathol Biol (Paris); 1992 May; 40(5):507-12. PubMed ID: 1495835
[TBL] [Abstract][Full Text] [Related]
12. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
[TBL] [Abstract][Full Text] [Related]
13. Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis.
Hope WW; Warn PA; Sharp A; Reed P; Keevil B; Louie A; Denning DW; Drusano GL
J Infect Dis; 2005 Aug; 192(4):673-80. PubMed ID: 16028137
[TBL] [Abstract][Full Text] [Related]
14. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models.
Brime B; Frutos P; Bringas P; Nieto A; Ballesteros MP; Frutos G
J Antimicrob Chemother; 2003 Jul; 52(1):103-9. PubMed ID: 12805269
[TBL] [Abstract][Full Text] [Related]
17. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
19. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
20. Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans.
van Etten EW; Chander HR; Snijders SV; Bakker-Woudenberg IA
J Antimicrob Chemother; 1995 Dec; 36(6):961-74. PubMed ID: 8821595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]